fig3

Figure 3. Biosafety assessment of PTTP-DCns in vitro. (A) Cell viabilities of MCF-7/ADR cells after being treated with different concentrations of PTTP-DCns for 48 h in the dark; (B) Cell viabilities of MCF-7/ADR cells pretreated with different concentrations of PTTP-DCns for 24 h, followed by the irradiation of a 525 nm LED light (0.2 mW·cm^-2, 30 min) and incubated for another 24 h. Data presented as mean ± SD. PTTP-DCns: Benzene-pyridothiadiazole-thienothiophene-pyridothiadiazole-benzene conjugated framework with quaternary ammonium-terminated n-carbon alkyl chains at both ends; MCF-7/ADR: Michigan Cancer Foundation-7/adriamycin-resistant; LED: light emitting diode; SD: standard deviation; PTTP-DC4/6/8: benzene-pyridothiadiazole-thienothiophene-pyridothiadiazole-benzene conjugated framework with quaternary ammonium-terminated C4/C6/C8 alkyl chains at both ends.